ورود
مقالات فارسیISIکنفرانسهاژورنالها

Screening for Femoral Head Osteonecrosis Following COVID-۱۹: Is It Worth It?

محل انتشار: مجله استخوان و جراحی عمومی، دوره: 11، شماره: 12
سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 61

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1845129

شناسه ملی سند علمی:

JR_TABO-11-12_001

تاریخ نمایه سازی: 15 آذر 1402

چکیده مقاله:

Objectives: Based on WHO data, as of June ۲۰۲۲, there were ۵۳۲.۲ million confirmed COVID-۱۹ cases globally.In the initial phase of the COVID -۱۹ pandemic, patients experiencing critical illness marked by severe respiratorydistress were commonly subjected to corticosteroid treatment. Regrettably, the administration of exogenouscorticosteroids stands as the prevailing cause of ONFH. In the current narrative review, we aim to evaluate if activescreening should be utilized to diagnose post-COVID-۱۹ ONFH in its early stages.Methods: The databases for PubMed, CINAHL, and Science Direct were systematically queried in March ۲۰۲۲.The search terms were as follows: “COVID-۱۹”, “severe acute respiratory syndrome”, “coronavirus”, “systemicsteroid”, “corticosteroid”, “femoral head osteonecrosis”, “avascular necrosis”, or “steroid therapy.” The includedstudies for review were all required to be peer-reviewed studies in the English language with Reported complicationslinked to steroid therapy in COVID-۱۹ patients or potential connections to the development of ONFH in individualsrecovering from the novel coronavirus have been documented.Results: Systemic corticosteroids were frequently employed in managing critically ill COVID-۱۹ patients. The CDCreports up to June ۲۰۲۲ showed more than ۴.۸ million COVID-۱۹ hospitalizations in the US, with approximately overone million patients receiving steroids. In a study of ONFH after infection with COVID-۱۹, all patients had bilateralinvolvement. The average duration from the initiation of corticosteroid treatment to the onset of symptoms was ۱۳۲.۸days.Conclusion: In summary, a distinct correlation exists between the administration of steroids to individuals with COVID۱۹ and the subsequent risk of ONFH. Moreover, an elevated dosage and prolonged duration of steroid therapy inCOVID-۱۹ patients are associated with an increased likelihood of developing ONFH. Therefore, active screening forhigh-risk patients, that may have received systemic corticosteroid treatment during a COVID-۱۹ illness, may bereasonable. Level of evidence: IV

کلیدواژه ها:

COVID-۱۹ ، Osteonecrosis of femoral head ، steroid

نویسندگان

Hamid Dolat Abadi

Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Parsa

۱ Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran ۲ American Hip Institute, Chicago, Illinois, USA

John Stelzer

UConn Health, Department of Orthopedic Surgery; Farmington, Connecticut, USA

Adam Anz

Andrews Institute for Orthopedics and Sports Medicine; Gulf Breeze, FL, USA

M. H. Ebrahimzadeh

Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Farshid Bagheri

Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Amirshahriar Ariamanesh

Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Neda Mirzaei

Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • World Health Organization. “WHO Coronavirus Disease (COVID-۱۹) Dashboard.” Available at: ...
  • Patel MK, Bergeri I, Bresee JS, et al. Evaluation of ...
  • Jv P, Vos J, Hoekstra E, Neumann K, Boot P, ...
  • Villar J, Confalonieri M, Pastores SM, Meduri GU. Rationale for ...
  • Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy ...
  • Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment ...
  • Cano EJ, Fuentes XF, Campioli CC, et al. Impact of ...
  • Dhasmana DJ. Dexamethasone in hospitalized patients with Covid-۱۹. N Engl ...
  • Abolghasemian M, Ebrahimzadeh MH, Enayatollahi M, et al. Iranian orthopedic ...
  • Guo K, Zhao F, Guo Y, Li F, Zhu L, ...
  • Wu L, Gao C, Wang G, et al. Clinical study ...
  • Hungerford DS, Jones LC. Asymptomatic osteonecrosis: should it be treated? ...
  • Ono K, Sugioka Y. Epidemiology and risk factors in avascular ...
  • Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. ...
  • Koo K-H, Mont MA, Cui Q, et al. The ۲۰۲۱ ...
  • Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, ...
  • Tan B, Li W, Zeng P, et al. Epidemiological study ...
  • Stockman LJ, Bellamy R, Garner P. SARS: systematic review of ...
  • Hui DS. Systemic corticosteroid therapy may delay viral clearance in ...
  • Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in ...
  • Pulakurthi YS, Pederson JM, Saravu K, et al. Corticosteroid therapy ...
  • Shetty GM. Double Trouble—COVID-۱۹ and the Widespread Use of Corticosteroids: ...
  • Daltro G, Silva I, Daltro P, Silva I, Botelho V. ...
  • Zhao R, Wang H, Wang X, Feng F. Steroid therapy ...
  • Wilson A, Murphy W, Hardy D, Totty W. Transient osteoporosis: ...
  • Hauzeur J-P, Malaise M, Gangji V. Osteonecrosis in inflammatory bowel ...
  • Kabata T, Matsumoto T, Yagishita S, Wakayama T, Iseki S, ...
  • Willis-Owen CA, Daurka JS, Chen A, Lewis A. Bilateral femoral ...
  • Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne ...
  • Berger CE, Kluger R, Urban M, Kowalski J, Haas OA, ...
  • Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, ...
  • Kubo T, Ueshima K, Saito M, Ishida M, Arai Y, ...
  • Weinstein RS. Glucocorticoid-induced bone disease. N Engl J Med.۲۰۱۱;۳۶۵(۱):۶۲-۷۰. doi: ...
  • Kim AY, Gandhi R. COVID-۱۹: Management in hospitalized adults. Available ...
  • National Institutes of Health. Therapeutic management of nonhospitalized adults with ...
  • Amer M, Kamel AM, Bawazeer M, et al. Clinical characteristics ...
  • Covid Data Tracker. Available at:https://covid.cdc.gov/covid-data-tracker/new-hospital-admissions. Accessed November ۲۴, ۲۰۲۳ ...
  • Law S, Leung AW, Xu C. Severe acute respiratory syndrome ...
  • Dhanasekararaja P, Soundarrajan D, Kumar KS, Pushpa BT, Rajkumar N, ...
  • Khot WY, Nadkar MY. The ۲۰۱۹ novel coronavirus outbreak-a global ...
  • ۴۱ Li T, Zhang Y, Wang R, et al. Discovery ...
  • Wee P, Wang Z. Regulation of EGFR endocytosis by CBL ...
  • Cao H-J, Zheng L-Z, Wang N, et al. Src blockage ...
  • Zhang L, Blackwell K, Workman LM, et al. TRAF۲ exerts ...
  • Yamato A, Soda M, Ueno T, et al. Oncogenic activity ...
  • Lee J-W, Hoshino A, Inoue K, et al. The HIV ...
  • Liu X, Li Q, Niu X, et al. Exosomes secreted ...
  • ۴۸ Okazaki S, Nishitani Y, Nagoya S, Kaya M, Yamashita ...
  • ۴۹ Adapala NS, Yamaguchi R, Phipps M, Aruwajoye O, Kim ...
    • نمایش کامل مراجع